Article of the day, September 13th, suggested by the Immune Oncology Research Institute

Immune Oncology Research Institute shared a post on LinkedIn:

“Article of the day! Suggest by the Immune Oncology Research Institute.

Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma

Authors: Ingo K. Mellinghoff, Martin J. van den Bent, Deborah T. Blumenthal, Mehdi Touat, Katherine B. Peters, Jennifer Clarke, Joe Mendez, Shlomit Yust-Katz, Liam Welsh, Warren P. Mason, François Ducray, Yoshie Umemura, Burt Nabors, Matthias Holdhoff, Andreas F. Hottinger, Yoshiki Arakawa, Juan M. Sepulveda, Wolfgang Wick, Riccardo Soffietti, James R. Perry, Pierre Giglio, Macarena de la Fuente, Elizabeth A. Maher, Steven Schoenfeld, Dan Zhao, Shuchi S. Pandya, Lori Steelman, Islam Hassan, Patrick Y. Wen and Timothy F. Cloughesy.

Author Affiliations: Memorial Sloan Kettering Cancer Center, Erasmus MC, Tel Aviv Medical Center, RABIN MEDICAL CENTER, Sorbonne Université, Institut du Cerveau – Paris Brain Institute, Hospices Civils de Lyon – HCL, CRCL Centre de Recherche en Cancérologie de Lyon, Duke University, Huntsman Cancer Institute, The Royal Marsden NHS Foundation Trust, Princess Margaret Cancer Centre, Sunnybrook, MIRO Cancer Centers/ Michigan Comprehensive Cancer Institute, Hospital Universitario 12 De Octubre, The Ohio State University Wexner Medical Center, et al.

Source: Immune Oncology Research Institute/LinkedIn

Immune Oncology Research Institute (IMMONC), established in 2022, is a non-profit, independent, patient-centered research institute. The mission of IMMONC is to advance the cancer knowledge and care through breakthrough scientific research, to integrate innovative immune-oncology therapies into the clinical practice for different types of cancers, to generate and collect clinical data for the identification of new therapeutic targets, developing predictive models and optimizing patient outcomes, to increase the availability and accessibility of those discoveries for the cancer patients, to create a world-class professional environment, to attract the brightest minds in cancer field and to train the next generation researchers.

Other posts featuring Immune Oncology Research Institute on OncoDaily.